These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9849413)

  • 1. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
    Ruiter DJ; Ferrier CM; van Muijen GN; Henzen-Logmans SC; Kennedy S; Kramer MD; Nielsen BS; Schmitt M
    Eur J Cancer; 1998 Aug; 34(9):1334-40. PubMed ID: 9849413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
    Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
    Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
    Romain S; Spyratos F; Lainé-Bidron C; Bouchet C; Guirou O; Martin PM; Oglobine J; Magdelénat H
    Eur J Clin Chem Clin Biochem; 1995 Sep; 33(9):603-8. PubMed ID: 8611670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
    Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA; Bergin FG; Leaper DJ
    Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
    Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
    Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
    Sier CF; Vloedgraven HJ; Ganesh S; Griffioen G; Quax PH; Verheijen JH; Dooijewaard G; Welvaart K; van de Velde CJ; Lamers CB
    Gastroenterology; 1994 Nov; 107(5):1449-56. PubMed ID: 7926508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
    Wagner SN; Atkinson MJ; Thanner S; Schmitt M; Wilhelm O; Rotter M; Höfler H
    J Pathol; 1996 May; 179(1):95-9. PubMed ID: 8691352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
    Sawai H; Liu J; Reber HA; Hines OJ; Eibl G
    Mol Cancer Res; 2006 Mar; 4(3):159-67. PubMed ID: 16547153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Hudson MA; McReynolds LM
    J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.